These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 31049142)
1. Guest Editors Henry Pownall and Antonio Gotto Offer Insight and Expertise on the topic of Lipids and Cardiovascular Disease. Methodist Debakey Cardiovasc J; 2019; 15(1):4. PubMed ID: 31049142 [No Abstract] [Full Text] [Related]
2. Lipids and Cardiovascular Disease: Putting It All Together. Pownall HJ; Gotto AM Methodist Debakey Cardiovasc J; 2019; 15(1):5-8. PubMed ID: 31049143 [No Abstract] [Full Text] [Related]
3. Reflections on a pioneer in the field of diet, lipids and vascular disease. Packard CJ Atherosclerosis; 2015 Dec; 243(2):656-7. PubMed ID: 26522437 [No Abstract] [Full Text] [Related]
6. Round table discussion: practical issues in the management of dyslipidaemic patients. Jacotot B; Betteridge J; Assmann G; Castelli W; Davignon J; Turpin G; Berthezene F Atherosclerosis; 1996 Jul; 124 Suppl():S89-97. PubMed ID: 8831921 [No Abstract] [Full Text] [Related]
7. More Nuanced Guidelines for Lipid Lowering to Prevent CVD. Shaughnessy AF Am Fam Physician; 2016 Jan; 93(1):59. PubMed ID: 26760843 [No Abstract] [Full Text] [Related]
8. Framing cardiovascular disease event risk prediction. Stone JA Can J Cardiol; 2011; 27(2):171-3. PubMed ID: 21459265 [No Abstract] [Full Text] [Related]
9. Current topics on hypolipidaemic therapy and cardiovascular risk assessment. Rizos EC; Elisaf MS Curr Vasc Pharmacol; 2010 Sep; 8(5):587-8. PubMed ID: 20572807 [No Abstract] [Full Text] [Related]
10. [25 years of progress in the treatment of metabolic disorders: statins revolutionise cardiovascular prevention]. Parhofer K MMW Fortschr Med; 2008 Nov; 150(48):95, 98. PubMed ID: 19125511 [No Abstract] [Full Text] [Related]
11. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003. Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG Atheroscler Suppl; 2004 Oct; 5(3):115-23. PubMed ID: 15531284 [No Abstract] [Full Text] [Related]
12. Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. Duntas L; Kolovou G Future Cardiol; 2011 Mar; 7(2):137-44. PubMed ID: 21453018 [No Abstract] [Full Text] [Related]
13. Implications of 4S evidence on baseline lipid levels. Ravnskov U Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7603244 [No Abstract] [Full Text] [Related]
14. Hyperlipidemia as a risk factor for cardiovascular disease. Nelson RH Prim Care; 2013 Mar; 40(1):195-211. PubMed ID: 23402469 [TBL] [Abstract][Full Text] [Related]
15. The New 2018 Cholesterol Guidelines. Khera A Circulation; 2019 Jun; 139(25):2805-2808. PubMed ID: 30586686 [No Abstract] [Full Text] [Related]
16. Terje Pedersen: a pioneer trialist in preventive cardiology. Morris K Lancet; 2010 Feb; 375(9716):717. PubMed ID: 20189014 [No Abstract] [Full Text] [Related]
17. Cardiovascular risk assessment and lipid modification: NICE guideline. Duerden M; O'Flynn N; Qureshi N Br J Gen Pract; 2015 Jul; 65(636):378-80. PubMed ID: 26120133 [No Abstract] [Full Text] [Related]
18. New drugs for reducing cardiovascular risk in women. Thacker HL; Saadi H Cleve Clin J Med; 1997 Oct; 64(9):493-502. PubMed ID: 9339048 [TBL] [Abstract][Full Text] [Related]